Fuks Z - Search Results

1

Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer.

Zelefsky MJ, Leibel SA, Wallner KE, Whitmore WF Jr, Fuks Z. Zelefsky MJ, et al. Among authors: fuks z. J Clin Oncol. 1995 Feb;13(2):459-63. doi: 10.1200/JCO.1995.13.2.459. J Clin Oncol. 1995. PMID: 7531221

2

Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.

Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, Leibel SA, Venkatraman ES. Zelefsky MJ, et al. J Clin Oncol. 2005 Feb 1;23(4):826-31. doi: 10.1200/JCO.2005.02.111. J Clin Oncol. 2005. PMID: 15681527

3

Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.

Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, Yamada Y, Vickers A, Scardino PT. Zelefsky MJ, et al. Among authors: fuks z. J Clin Oncol. 2010 Mar 20;28(9):1508-13. doi: 10.1200/JCO.2009.22.2265. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159826 Free PMC article.

4

Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer.

Padula GD, Zelefsky MJ, Venkatraman ES, Fuks Z, Lee HJ, Natale L, Leibel SA. Padula GD, et al. Among authors: fuks z. Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):439-43. doi: 10.1016/s0360-3016(01)02604-9. Int J Radiat Oncol Biol Phys. 2002. PMID: 11872290

5

Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer.

Levegrün S, Jackson A, Zelefsky MJ, Venkatraman ES, Skwarchuk MW, Schlegel W, Fuks Z, Leibel SA, Ling CC. Levegrün S, et al. Among authors: fuks z. Radiother Oncol. 2002 Apr;63(1):11-26. doi: 10.1016/s0167-8140(02)00062-2. Radiother Oncol. 2002. PMID: 12065099

6

Intensity-modulated radiation therapy for prostate cancer.

Zelefsky MJ, Fuks Z, Leibel SA. Zelefsky MJ, et al. Among authors: fuks z. Semin Radiat Oncol. 2002 Jul;12(3):229-37. doi: 10.1053/srao.2002.00000. Semin Radiat Oncol. 2002. PMID: 12118388 Review.

7

High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients.

Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA. Zelefsky MJ, et al. Among authors: fuks z. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1111-6. doi: 10.1016/s0360-3016(02)02857-2. Int J Radiat Oncol Biol Phys. 2002. PMID: 12128109

8

Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer.

Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA. Katz MS, et al. Among authors: fuks z. J Clin Oncol. 2003 Feb 1;21(3):483-9. doi: 10.1200/JCO.2003.12.043. J Clin Oncol. 2003. PMID: 12560439 Clinical Trial.

9

Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.

Zelefsky MJ, Marion C, Fuks Z, Leibel SA. Zelefsky MJ, et al. Among authors: fuks z. J Urol. 2003 Nov;170(5):1828-32. doi: 10.1097/01.ju.0000093720.46502.24. J Urol. 2003. PMID: 14532785

10

Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer.

Leibel SA, Fuks Z, Zelefsky MJ, Hunt M, Burman CM, Mageras GS, Chui CS, Jackson A, Amols HI, Ling CC. Leibel SA, et al. Among authors: fuks z. Semin Oncol. 2003 Oct;30(5):596-615. doi: 10.1016/s0093-7754(03)00354-3. Semin Oncol. 2003. PMID: 14571409 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

434 results

Search Page

Filters